XORTX Therapeutics Inc.
XRTX
$0.45
-$0.02-4.24%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 25.98% | -17.44% | |||
| Depreciation & Amortization | -1.02% | 6.52% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 20.80% | -30.56% | |||
| Operating Income | -20.80% | 30.56% | |||
| Income Before Tax | 9.08% | 9.50% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 9.08% | 9.50% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 9.08% | 9.50% | |||
| EBIT | -20.80% | 30.56% | |||
| EBITDA | -21.19% | 30.77% | |||
| EPS Basic | 32.54% | 29.45% | |||
| Normalized Basic EPS | 32.78% | 29.39% | |||
| EPS Diluted | 32.54% | 29.63% | |||
| Normalized Diluted EPS | 32.78% | 29.39% | |||
| Average Basic Shares Outstanding | 34.76% | 28.20% | |||
| Average Diluted Shares Outstanding | 34.76% | 28.20% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||